Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14130983 | 0.97 | P2RY12 (0.52) | P2RY12MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL14130740 | 0.94 | P2RY12 (0.52) | P2RY12MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4723473 | 0.92 | P2RY12 (0.54) | P2RY12MEN1ALDH1A1GAAMAPT | |
| SCHEMBL14130826 | 0.92 | P2RY12 (0.53) | P2RY12MEN1ALDH1A1KMT2A | |
| SCHEMBL14130823 | 0.90 | P2RY12 (0.54) | P2RY12MEN1ALDH1A1KMT2A | |
| SCHEMBL4721246 | 0.90 | P2RY12 (0.54) | P2RY12MEN1ALDH1A1KMT2A | |
| SCHEMBL14130794 | 0.89 | P2RY12 (0.61) | P2RY12MEN1ALDH1A1KMT2A | |
| SCHEMBL4765245 | 0.89 | P2RY12 (0.54) | P2RY12MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL14130690 | 0.89 | P2RY12 (0.53) | P2RY12MEN1ALDH1A1KMT2A | |
| SCHEMBL14130978 | 0.88 | P2RY12 (0.54) | P2RY12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | P2RY12 17/4885MEN1 4451/4885ALDH1A1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.